Biotech capital markets delivered two large financing events this week. Erasca closed an upsized public offering of 25.875 million shares at $10.00 per share, generating roughly $258.8 million in gross proceeds to fund its RAS/MAPK-focused clinical programs. The company sold all shares in the offering and exercised the underwriters’ option in full. In private financing activity, Corxel Pharmaceuticals completed a $287 million Series D to advance CX-11, an oral GLP‑1 receptor agonist for obesity and overweight patients. The cash will support late‑stage development and commercialization preparation for an oral small‑molecule GLP‑1 program. Together, the transactions illustrate sustained investor appetite for both oncology biotech with clinical pipelines and obesity therapeutics positioned for high commercial demand.